

REVIEW

Open Access



Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis

Martina Contarini^{1†}, Amelia Shoemark^{2*†}, Jessica Rademacher³, Simon Finch², Andrea Gramegna¹, Michele Gaffuri⁴, Luca Roncoroni⁴, Manuela Seia⁵, Felix C. Ringshausen³, Tobias Welte³, Francesco Blasi¹, Stefano Aliberti^{1*} and James D. Chalmers²

From 2nd World Bronchiectasis Conference
Milan, Italy. 06-08 July 2017

Abstract

Bronchiectasis represents the final pathway of several infectious, genetic, immunologic or allergic disorders. Accurate and prompt identification of the underlying cause is a key recommendation of several international guidelines, in order to tailor treatment appropriately. Primary ciliary dyskinesia (PCD) is a genetic cause of bronchiectasis in which failure of motile cilia leads to poor mucociliary clearance. Due to poor ciliary function in other organs, individuals can suffer from chronic rhinosinusitis, otitis media and infertility.

This paper explores the current literature describing why, when and how to investigate PCD in adult patients with bronchiectasis. We describe the main PCD diagnostic tests and compare the two international PCD diagnostic guidelines. The expensive multi-test diagnostic approach requiring a high level of expertise and specialist equipment, make the multifaceted PCD diagnostic pathway complex. Therefore, the risk of late or missed diagnosis is high and has clinical and research implications.

Defining the number of patients with bronchiectasis due to PCD is complex. To date, few studies outlining the aetiology of adult patients with bronchiectasis conduct screening tests for PCD, but they do differ in their diagnostic approach. Comparison of these studies reveals an estimated PCD prevalence of 1–13% in adults with bronchiectasis and describe patients as younger than their counterparts with moderate impairment of lung function and higher rates of chronic infection with *Pseudomonas aeruginosa*.

Diagnosing PCD has clinical, socioeconomic and psychological implications, which affect patients' life, including the possibility to have a specific and multidisciplinary team approach in a PCD referral centre, as well as a genetic and fertility counselling and special legal aspects in some countries.

To date no specific treatments for PCD have been approved, standardized diagnostic protocols for PCD and recent diagnostic guidelines will be helpful to accurately define a population on which planning RCT studies to evaluate efficacy, safety and accuracy of PCD specific treatments.

Keywords: Bronchiectasis, Primary ciliary dyskinesia, Adult, Aetiology

* Correspondence: a.shoemark@dundee.ac.uk; stefano.aliberti@unimi.it

[†]Martina Contarini and Amelia Shoemark contributed equally to this work.

²Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

¹Department of Pathophysiology and Transplantation, University of Milan, Internal Medicine Department, Respiratory unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy

Full list of author information is available at the end of the article



Background

Bronchiectasis is a chronic respiratory disease characterized by permanent dilatation of the bronchi and associated with a clinical syndrome of cough, sputum production and recurrent respiratory infections, with attributable morbidity and mortality rates [1, 2]. Although epidemiological data are limited, recent literature suggests that bronchiectasis is far from being a rare disease [3]. Different European datasets describe an increasing prevalence of bronchiectasis with current rates estimated at 53 to 566 cases *per* 100,000 inhabitants [4–6]. Bronchiectasis represents the final pathway of several infectious, genetic, immunologic or allergic disorders which helps explain the extreme heterogeneity of the disease [7]. Identifying the underlying cause both accurately and quickly is a key recommendation of several international guidelines, as many aetiologies of bronchiectasis are treatable or have specific prognostic implications [8].

Primary ciliary dyskinesia (PCD) is widely recognized as an aetiology of bronchiectasis not only in children or young adults but also in older patients [9–11]. PCD is a rare disorder with an estimated prevalence of 1:10,000 [12] caused by mutations in more than 30 genes which leads to functional and/or structural defects of motile cilia [13, 14]. Cilia are specialized hair-like motile or non-motile structures, containing nine pairs of microtubules in a peripheral and radial distribution with a central pair of microtubules. Motile ciliated epithelial cells are present in the nasal cavity, paranasal sinuses, middle ear, airways, fallopian tube, cervix, vas deferens and ependyma. Respiratory cilia mediate the propulsion and expulsion of the mucus layer through coordinated movements (mucociliary clearance). PCD-causing mutations result in immotile or ineffective ciliary beating and consequently in abnormal mucociliary clearance and chronic bacterial infection. This inflammatory and infectious process leads to chronic rhinosinusitis and otitis media, progressive airway obstruction, bronchiectasis and ultimately respiratory failure [15]. In addition, failure of effective motile cilia function in the embryonic node leads to situs inversus in ~50% patients with PCD. Sperm flagella and cilia of the fallopian tubes share common axonemal structures with motile cilia of the respiratory system, so a proportion of PCD-affected males and females are infertile [16].

Why is it important to diagnose PCD in adults with bronchiectasis?

Although the optimal series of tests to investigate bronchiectasis aetiology is still under debate, most of the clinical and scientific community underline the need to investigate and diagnose PCD in adults with bronchiectasis because of its clinical, social-economic and psychological implications. From a clinical perspective, PCD is a multi-system disease with extra-respiratory involvement

which benefits from a specific, comprehensive and multidisciplinary team approach in a PCD referral centre [1, 17]. A prompt and accurate diagnosis should be provided to patients because a late diagnosis is associated with an impairment of respiratory function as determined by decreased forced expiratory volume in the 1st second (FEV₁), and increased likelihood of chronic *Pseudomonas aeruginosa* infection [18]. Furthermore, PCD is a hereditary disorder and patients and their families may require referral to genetic and reproductive counselling services [17].

PCD therapeutic approach largely mimics treatment for other chronic respiratory diseases such as cystic fibrosis (CF) and non-CF bronchiectasis. Chest physiotherapy, including adjunct long-term mucoactive treatment like nebulized hypertonic saline, and specific pulmonary rehabilitation programmes are the cornerstones of PCD long-term therapy [19], accompanied by prompt antibiotic courses for exacerbations guided by historical sputum cultures [17]. Moreover, upper airway involvement may require a disease specific approach, including otolaryngology and audiology counselling [17], as it delivers significant symptom burden and puts patients at risk for sinonasal infections and subsequent pulmonary exacerbations. Hearing aids may be indicated in a considerable number of adult PCD patients. Diagnostic nasal sinus lavage for microbiologic sampling may be reasonable, when chronic infection or inflammation of the paranasal sinuses is suspected or when persistent rhinosinusitis is present. Daily sinonasal saline irrigation may be required for the moisturisation of the nasal mucosa.

To date, no specific treatments for PCD are approved. A multi-centre RCT of six-months azithromycin maintenance therapy is currently ongoing [20]. However, our understanding of the molecular biology of PCD is rapidly improving and in the near future we may see different treatment options for this group of patients. An example of this is the current CLEAN-PCD trial testing the VX-371 compound, an inhaled epithelial sodium channel (ENaC) inhibitor, that improves airway hydration and mucociliary clearance blocking the reabsorption of sodium in the airway surface liquid. The CLEAN-PCD trial is an ongoing international, phase II, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of VX-371 inhalation with or without oral Ivacaftor in patients with PCD (NCT02871778).

From a socioeconomic point of view, PCD patients have access to free care and proper health insurance issues in some countries and/or might benefit from special legislation. From a psychological perspective, PCD is a disabling chronic disease with implications for patients' life plans. Most PCD patients, both male and female, have an increased risk of fertility problems which may

go undetected for a long time. Therefore, fertility counselling should be included in PCD standard of care and offered to patients when appropriate [16]. Finally, and above all, patients wish to have a diagnosis and know the reason for their symptoms [21].

When should PCD be investigated in adults with bronchiectasis?

There are no publications which directly address whether routine aetiological investigation protocols provide benefits in terms of morbidity compared to clinically driven investigations or no testing. The recent guidelines published by the European Respiratory Society (ERS) suggest a *minimum* bundle of aetiological tests to be performed in adults with a new diagnosis of bronchiectasis, including differential blood count, serum immunoglobulins and testing for allergic bronchopulmonary aspergillosis [8]. Testing for PCD is limited to patients with clinical features consistent with the disease: persistent productive cough since childhood, nasal polyposis and/or chronic rhinosinusitis, chronic middle ear disease with or without hearing loss, situs anomalies, congenital cardiac defects and a history of neonatal respiratory distress or neonatal intensive care admittance in term infants. These clinical factors are included in the PICADAR score, a simple diagnostic clinical tool to predict whether symptomatic patients have PCD [22]. Most bronchiectasis guidelines agree with this diagnostic approach targeted on patient clinical features, underlining the importance of evaluating a history of symptoms from upper and lower respiratory tract that goes back to childhood [1, 8, 23]. However, some tertiary referral centres with expertise in PCD testing investigate PCD in most of their bronchiectasis patients [24, 25]. A study shows how a full investigation of aetiologies in adults with bronchiectasis allow diagnosis of PCD in patients without a strong history consistent with the disease. In a cohort of 240 people presenting with chronic productive cough and recurrent chest infections, PCD was found in 17 (10%) patients with a mean age of 36 years (36 ± 13) [11]. This suggests that the prevalence of PCD is greater than is currently known and should be suspected also in adults without typical PCD clinical features, in particular as clinical presentation may vary according to age.

How to diagnose PCD in adults with bronchiectasis?

ERS guidelines propose a combination of tests to diagnose PCD, including nasal nitric oxide, high-speed video analysis, transmission electron microscopy, immunofluorescence and genetics. Due to poor sensitivity and specificity of many of these modalities, multiple tests rather than a hierarchical strategy of testing are suggested [8]. A short description of PCD diagnostic tests is presented below.

Clinical presentation

PICADAR and modified PICADAR

PICADAR is a simple diagnostic clinical tool to predict whether patients with persistent productive cough are likely to have PCD [22]. It has seven predictive parameters (full-term gestation, neonatal chest symptoms, neonatal intensive care admittance, situs inversus, congenital cardiac defect, chronic rhinitis and ear symptoms) and each contributes a weighted score (1–4) to give a maximum of 14 points. The best discriminative cut-off of the score is 5 points, with a sensitivity of 90% and a specificity of 75%. PICADAR has a good accuracy and has already been validated internally and externally, with an Area Under the Curve of 0.91 and 0.87, respectively. However, most adults do not remember their gestational age or what happened immediately after their birth. Therefore, a modified PICADAR has been recently created to overcome this problem: “gestational age” is omitted and “neonatal chest symptoms” and “admittance to a neonatal unit” are combined to a more general “neonatal respiratory distress” [25]. Each parameter contributes again with 1 to 4 points to the total score, but the best discriminate cut-off is 2, with a sensitivity of 100% and a specificity of 89%. This modified score requires further prospective testing in adult cohorts.

Although both scores have easy and quick items to compute and could be used to decide which patients to refer to further PCD tests, they cannot be used in isolation, because of their limited sensitivity and specificity.

In summary, suspicion based upon history and clinical presentation is essential. Additional historical and clinical features commonly observed in subjects with PCD include parental consanguinity, pectus excavatum and scoliosis [26, 27]. Chest high-resolution computer tomography (HRCT) features can also be helpful in raising PCD suspicion. Typical findings are the characteristic distribution, extent and severity (predominantly middle and lower lobe involvement) the presence of mucus plugging, tree in bud phenomenon, atelectasis, history of middle or lower lobe resection and situs inversus [28].

Nasal nitric oxide (nNO)

Measurement of nNO is one of the first steps in the PCD diagnostic flowchart, because it is non-invasive, affordable and relatively easy to perform, especially thanks to the increasing availability of electrochemical portable analyzers [29]. Therefore, nNO superseded saccharin test, a previous test of nasal mucociliary clearance, no longer advocated because it is not suitable for small children and is prone to false positive and negative results [30].

Nasal NO is used in the PCD diagnostic algorithm because nNO levels are extremely low in most patients with PCD when compared to healthy and disease controls [31]. The reason behind this low nNO is unknown.

Many hypotheses have been proposed so far, including a reduced biosynthesis of nitric oxide (NO) by the airway epithelium [32]; an increased breakdown of NO to metabolites within respiratory cells or by denitrifying bacteria [33]; a reduced storage capacity of NO in the paranasal sinuses [34] and NO trapped in the obstructive paranasal sinuses [35], but none of them is unanimously accepted.

There is also no consensus on the most appropriate technique for velum closure, analyser sampling rate (to which the measurement is sensitive) or what nNO threshold constitutes a positive or negative cut-off [36]. Leigh and colleagues developed a threshold of 77 nL/min using a conversion calculation which is reported to account for analyser differences with a sensitivity of 99% and a specificity of 75% [37]; Beydon and co-workers used a cut-off of 82 nL/min, reporting a sensitivity of 91% and a specificity of 86% [38], whereas Jackson and colleagues provided a sensitivity and specificity of 91 and 96%, respectively, with a threshold of 30 nL/min [39]. To date, 77 nL/min is one of the most used nNO cut-off and has been accepted as a diagnostic criterion for PCD by the North America PCD Foundation [17].

Many conditions though reduce nNO levels, including nasal polyps [40], chronic sinusitis [41], diffuse pan-bronchiolitis [42], cystic fibrosis (CF) [43], HIV infection [44] and smoking [45]. In addition, PCD genotypes associated with normal nNO levels have been increasingly reported [46, 47]. Therefore, although the value of nNO as part of the diagnostic algorithm for PCD is clear, its lack of specificity prevents it from being used in isolation to rule PCD in or out [36]. So, patient's clinical history should be considered in conjunction with nNO results when deciding whether to proceed with a nasal brush biopsy [48].

High-speed video analysis (HSVA)

Ciliary function can be analyzed *ex vivo* by the assessment of respiratory ciliary activity in epithelium obtained by cytology brush from the nose or bronchus. A camera attached to the microscope records at high speeds (120–500 frames per second – fps –) and video can be replayed slower (30–60 fps) to measure ciliary beat frequency (CBF) and review ciliary beat pattern (CBP) [49]. However, this requires considerable expertise, and there is no consensus on appropriate cell processing and method of ciliary assessment. Therefore, standardized protocols and thresholds need to be developed for *ex vivo* analysis of CBF and CBP. Ciliated cells can be observed immediately after sampling and again after a period of culturing to differentiate PCD from secondary dyskinesia, a ciliary defect caused by infection and inflammation of the airways [50]. Secondary ciliary dyskinesia can affect CBF (low CBF) and CBP (poor coordination of ciliary beating,

lack of full sweep and mucus impedance) and therefore repeating the analysis following cell culture in the presence of antibiotics is sometimes recommended to differentiate it from a primary defect [36].

Transmission electron microscopy (TEM)

The evaluation of ciliary ultrastructural defects is a key part of the diagnostic work-up. TEM is a highly specific test, considered for many years the “gold standard” diagnostic test for PCD, because it can detect lack of dynein arms [51], disorganizations of microtubular doublets [52] or loss of the central microtubular pair [53]. However, TEM should not be used in isolation to exclude a PCD diagnosis, because standardized protocols and consensus on terminology, especially regarding the number and proportion of cilia required to make a diagnosis, are lacking and 15–30% of patients with PCD have apparently normal ciliary ultrastructure, for example those with a pathogenic variant in DNAH11 [36, 54]. It is important to underline that acquired defects can be associated with transient ultrastructural abnormalities (disrupted membranes, compound cilia, additional tubules and axonemal blebs) [50], so repeating TEM after cell culture may be helpful in equivocal cases.

Immunofluorescence

Immunofluorescence (IF) can help confirm PCD using fluorescent antibodies to stain ciliated respiratory epithelium obtained by nasal brushing. IF can detect the absence of key ciliary proteins such as the DNAH5 heavy chain of the outer dynein arm [55]. IF may identify some cases where TEM is apparently normal or subtly abnormal [56, 57] and it is cheaper and quicker than TEM, but, although its accuracy has recently been determined, its sensitivity remains limited [58]. Many PCD mutations and structural cilia proteins have not been identified yet and false negative results may occur, but gene discovery and antibody development are likely to improve immunofluorescence sensitivity and technique.

Genetics

Genetic testing for disease-causing mutations can be performed in patients suspected of having PCD to confirm the diagnosis such as those with normal ultrastructure by TEM or in already confirmed PCD patients to provide a genetic diagnosis. Non-ambiguous bi-allelic autosomal mutations or hemizygous X-linked mutations are identified in 50–75% of cases [59]. To date, more than 1000 disease causing variants across more than 35 genes have been described and the most common are in the dynein heavy chains DNAH5 and DNAH11 [60]. However, not all PCD mutations are known and accuracy of genetic testing is still lacking.

Diagnostic testing guidelines

Currently there are two specific PCD guidelines that propose diagnostic criteria and describe diagnostic tests: the guidelines published by ERS [36] and the consensus recommendations published by the North American PCD Foundation [17]. They differ in many aspects. First of all, ERS guidelines are evidence-based guidelines, whereas the American Genetic Disorders of Mucociliary Clearance Consortium (GDMCC) created a consensus statement. The American recommendations distinguish PCD diagnostic criteria by age and define PCD diagnosis according to the presence of two or more major clinical criteria (unexplained neonatal respiratory distress, any organ laterality defects, chronic wet cough and rhinosinusitis since childhood) plus at least one positive diagnostic test (nNO, HSVA, TEM and genetics). ERS, instead, do not distinguish PCD diagnostic criteria by age, but provide a diagnostic algorithm with a step-wise approach ending in different outcomes: PCD positive, PCD highly likely and PCD extremely unlikely.

The two publications differ also in some diagnostic test aspects. The American statement recommends 77 nL/min as nNO threshold, whereas ERS guidelines cannot find a consensus on the appropriate nNO cut-off. ERS guidelines recommend the use of HSVA before and after cellular

culture as an important diagnostic tool, while the American statement, although recognizing its importance, underlines the fact that few centres have expertise to perform these tests.

The ERS guidelines and the American statement share also some similarities: both include infants and adults; both could not recommend IF as a diagnostic tool because studies were lacking, although these studies have now been performed [58] and both advise against the use of TEM in isolation to exclude PCD because some patients with PCD show apparently normal ultrastructure.

The comparison between the two publications is summarized in Table 1.

Prevalence of PCD in adults with bronchiectasis

Defining the prevalence of PCD in adults with bronchiectasis is challenging.

Some epidemiological information comes from papers that, despite having other aims, describe adult bronchiectasis populations and briefly their aetiologies, including ciliary dysfunction [61–68].

Other studies are focused on defining the demographic characteristics and identifying the aetiologies of patients with bronchiectasis, but do not describe the criteria used to diagnose PCD [69–73], or do not describe any PCD

Table 1 A comparison between European Respiratory Society (ERS) and North American primary ciliary dyskinesia (PCD) Foundation guidelines

	ERS 2017 [36]	North American PCD Foundation 2016 [17]
Structure	Evidence-based guidelines	Consensus statement
Patients included	Infants and adults	Infants and adults
Diagnostic criteria distinguished by age	Not done	Newborns (0–1 month) Children (1 month – 5 years) Children 5–18 years and adults
Diagnostic criteria	A diagnostic algorithm is proposed	Two major clinical criteria PLUS at least one diagnostic test
Diagnostic outcome	PCD positive, PCD highly likely and PCD extremely unlikely	PCD positive and PCD negative
nNO	No consensus on appropriate thresholds	< 77 nL/min on 2 occasions, > 2 months apart, with CF excluded
HSVA	Several European centres employ HSVA due to high expertise	No American centres can reliably perform HSVA due to lack of expertise
Cell culture	Recommended to improve accuracy of HSVA and TEM to rule out a false positive diagnosis or support a highly likely diagnosis	Not mentioned
IF	Not included in the diagnostic algorithm due to lack of studies at time of guideline	Not included in the diagnostic criteria due to lack of studies at time of guideline
TEM	Can be used to confirm a diagnosis but advise against TEM in isolation to exclude PCD because some patients with PCD have apparently normal ultrastructure	Can be used to confirm a diagnosis but advise against TEM in isolation to exclude PCD because some patients with PCD have apparently normal ultrastructure
Genotyping	Can be used to confirm a diagnosis but cannot be used to exclude a diagnosis because evidence on sensitivity and specificity lacks	Can be used to confirm a diagnosis but cannot be used to exclude a diagnosis because evidence on sensitivity and specificity lacks

PCD Primary ciliary dyskinesia, nNO Nasal nitric oxide, CF Cystic fibrosis, HSVA High-speed video analysis, IF Immunofluorescence, TEM Transmission electron microscopy

Table 2 Comparison between studies evaluating aetiologies of bronchiectasis in adult patients

Paper	Type and site of study	Patients involved	Patients screened for PCD	PCD diagnosed	Screening tests	Diagnosis tests	Features of PCD population
Amorim, 2015 [77]	Monocentric, Retrospective, Cohort study Portugal	202	5 with history of infertility	1 (0.5%)	Semen analysis	Not mentioned	Not mentioned
Kadowaki, 2015 [78]	Monocentric, Retrospective, Cohort study Japan	147	147	2 (1%)	Kartagener's features	Kartagener's features	Not mentioned
Verra, 1991 [79]	Monocentric, Prospective, Cohort study France	53	38 with diffuse bronchiectasis	5 (13%)	Chest HRCT	TEM	Prevalence in North African patients 36% Prevalence in European patients 4%
Pasteur, 2000 [80]	Monocentric, Prospective, Cohort study United Kingdom	150	150	1 (0.6%)	Light microscopy with CBF	TEM	Not mentioned
King, 2006 [81]	Monocentric, Prospective, Cross-sectional Australia	103	103	1 (1%)	Unexplained infertility	Ciliary function	Not mentioned
Shoemark, 2007 [11]	Monocentric, Prospective, Cohort study United Kingdom	240	240	17 (10%) 12 PCD positive 5 PCD likely	Saccharin test nNO	Light microscopy TEM	Age 36 ± 13
Anwar, 2013 [82]	Two centres Prospective, Cohort study United Kingdom	189	189	2 (1%)	History of upper and lower respiratory symptoms and/or infertility	Referral to specialized PCD centre	Not mentioned
Qian, 2015 [83]	Multi-centre, Prospective, Cohort study China (Chinese Han ethnicity)	476	71 with history of upper and lower respiratory symptoms or Kartagener's features	4 (0.9%)	Saccharin test	TEM	Not mentioned
Lonni, 2015 [24]	Multicentre, International, Prospective, Cohort study Italy United Kingdom Spain Greece Belgium Ireland	1258	Not mentioned	21 (1.7%)	History of upper and lower respiratory symptoms Saccharin test nNO	Referral to specialized PCD centre	Younger than 50 years Non-smokers Mild disease 11 (52.4%) Moderate 8 (38.1%) Severe 2 (9.5%)

Table 2 Comparison between studies evaluating aetiologies of bronchiectasis in adult patients (Continued)

Paper	Type and site of study	Patients involved	Patients screened for PCD	PCD diagnosed	Screening tests	Diagnosis tests	Features of PCD population
Guan, 2015 [84]	Multicentre, Prospective, Cohort study China	148	148	2 (1.4%)	Saccharin test	Kartagener's features	Younger than other bronchiectasis patients
Dimakou, 2016 [85]	Monocentric, Prospective, Cohort study Greece	277	32 with history of respiratory distress syndrome after birth, of upper and lower respiratory symptoms since childhood and/or infertility	12 (4%)	Saccharin test nNO	TEM	Not mentioned
Olveira, 2017 [86]	Multi-centre, Prospective, Cross-sectional Spain	2047	Not mentioned	60 (2.9%)	Clinical features Saccharin test Seroalbumin NO (not specified if FE _{NO} or nNO)	TEM	Age 42.9 ± 8.8 Age at diagnosis 22.1 ± 18.1 Male 29 (48.3%) Smokers 14 (23.3%) BMI 23.8 ± 6.1 FEV ₁ (%) 67.1 ± 24.2 Chronic Infection Pa 27 (45%) Inhaled ATB 21 (39.6%) Bilateral bronchiectasis 29 (48.3%)

Features of PCD populations are presented as mean ± SD or number (%)

PCD Primary ciliary dyskinesia, HRCT High-resolution computed tomography, nNO Nasal nitric oxide, HSVA High-speed video analysis, TEM Transmission electron microscopy, CBF Ciliary beat frequency, FE_{NO} Orally exhaled nitric oxide, SD Standard deviation

patients in their cohorts [74–76]. To our knowledge, two retrospective studies and ten prospective studies outline the aetiology of adults with bronchiectasis and conduct screening tests for PCD [11, 24, 77–86]. As regards the PCD diagnostic approach though, they differ in many aspects. Most studies use clinical features and history of upper and lower respiratory symptoms and/or infertility as a PCD screening method for further testing [24, 77, 78, 81–83, 85, 86], while one study performs chest high-resolution computed tomography (HRCT) to find diffuse bronchiectasis, considering it a characteristic to investigate for PCD [79].

The studies differ also in the selection of further tests: saccharin test alone [83]; saccharin test and/or nNO [24, 85]; saccharin test, NO test or nasal mucociliary clearance by sero-albumin [86]. Finally, TEM [79, 82, 85], ciliary function [81] or referral patients to a PCD centre [24, 82] are chosen as diagnostic approach to confirm PCD.

Three studies test all adult bronchiectasis patients for PCD, but again they select different assessments: saccharin test [84], saccharin test plus nNO [11] and light microscopy for the CBF [80] as first steps; TEM [80], HVA plus TEM [11] and Kartagener's features [84] to confirm PCD diagnosis.

In all the mentioned studies PCD prevalence varies from 1 to 13% in adults with bronchiectasis, but different screening tools and diagnostic tests make this assessment quite difficult to interpret. It will be of interest to see the effect of the recently published diagnostic guidelines on the approach to such studies going forward.

Some of the prospective studies describe the resultant PCD cohort. PCD patients who have been identified are younger than other bronchiectasis patients [11, 24, 84, 86], without differences in gender prevalence and non-smokers [24, 86]. They have a higher prevalence of bilateral bronchiectasis (48.3%) and a moderate impairment of FEV₁ (67.1% ± 24.2) [86]. PCD patients have higher rates of chronic infection with *P. aeruginosa* (45%) and are treated with chronic inhaled antibiotic more frequently (39.6%) when compared with other patients with bronchiectasis [86].

The comparison between the publications is summarized in Table 2.

PCD published studies are few with low numbers of patients involved. Recently, two large international registries (iPCD Cohort and International PCD registry) have been created, including over 3000 PCD patients [9, 10]. Although these registries have the strength of assessing differences in PCD characteristics and management between countries and ethnic groups, they have also some limitations in defining what a positive diagnosis of PCD is. They also have a predominance of

paediatric patients, suggesting adults with PCD are being neglected from a research perspective.

Conclusion

Physicians treating bronchiectasis patients should suspect the diagnosis of PCD in adults, in order to offer appropriate care. The requirement for a multi-test diagnostic approach where some tests are very expensive, some requiring a high level of expertise and specialist equipment, make the multifaceted PCD diagnostic pathway complex. Therefore, the risk of heterogeneous, late or missed diagnosis is high [9, 18] and has clinical and research implications. Standard diagnostic protocols for PCD will be helpful to accurately define a population on which planning RCT studies to evaluate efficacy, safety and accuracy of treatments.

Funding

Not applicable. Publication costs of this article will be funded by Novamedia and Italian Respiratory Society (IRS).

About this supplement

This article has been published as part of *Multidisciplinary Respiratory Medicine* Volume 13 Supplement 1, 2018: Bronchiectasis: still an orphan disease?. The full contents of the supplement are available online at <https://mrmjournal.biomedcentral.com/articles/supplements/volume-13-supplement-1>.

Authors' contributions

MC and AS have been involved in drafting the manuscript; JC and SF have been involved in revising it critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests. Prof. Francesco Blasi is Editor-in-Chief of *Multidisciplinary Respiratory Medicine*, whereas Prof. Tobias Welte and Stefano Aliberti are Associate editors of *Multidisciplinary Respiratory Medicine*. In addition, Profs. Stefano Aliberti and James D Chalmers are Guest Editors of the Supplement on Bronchiectasis.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Pathophysiology and Transplantation, University of Milan, Internal Medicine Department, Respiratory unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy. ²Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. ³Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research (DZL), Hannover, Germany. ⁴Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. ⁵Medical Genetics Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Published: 9 August 2018

References

- Pasture MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. *Thorax*. 2010;65(Suppl 1):i1–58.
- McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. *Lancet Respir Med*. 2016;4(12):969–79.
- Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. *Eur Respir J*. 2016; 47(1):186–93.
- Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, Simonet P, Miravittles M. Prevalence and incidence of bronchiectasis in Catalonia, Spain: a population-based study. *Respir Med*. 2016;121:26–31.
- Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. *Eur Respir J*. 2015;46(6):1805–7.
- Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. *Clin Pulm Med*. 2005;12:205–9.
- Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European bronchiectasis registry: protocol for an international observational study. *ERJ Open Res*. 2016;2(1), <https://doi.org/10.1183/23120541.00081-2015>.
- Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J*. 2017;50(3), <https://doi.org/10.1183/13993003.00629-2017>.
- Goutaki M, Maurer E, Halbeisen FS, Amirav I, Barbato A, Behan L, et al. The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results. *Eur Respir J*. 2017;49:1601181.
- Werner C, Lablans M, Ataian M, Raidt J, Wallmeier J, Große-Onnebrink J, et al. An international registry for primary ciliary dyskinesia. *Eur Respir J*. 2016;47:849–59.
- Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. *Respir Med*. 2007;101(6):1163–70.
- Kuenhi CE, Lucas JS. Diagnosis of primary ciliary dyskinesia: summary of the ERS task force report. *Breathe (Sheff)*. 2017;13(3):166–78.
- Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Bakhtai G, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. *Eur Respir J*. 2009;34:1264–76.
- Lucas JS, et al. Primary ciliary dyskinesia. In: Courdier JF, editor. *Orphan lung diseases (ERS monograph)*. Sheffield: European Respiratory Society; 2011. p. 201–17.
- Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. *Am J Respir Crit Care Med*. 2004;169(4):459–67.
- Vanaken GJ, Bassinet L, Boon M, Mani R, Honoré I, Papon JF. Infertility in an adult cohort with primary ciliary dyskinesia: phenotype–gene association. *Eur Respir J*. 2017;50:1700314.
- Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. *Pediatr Pulmonol*. 2016;51:115–32.
- Shaha A, Shoemark A, MacNeill SJ, Bhaludin B, Rogers A, Bilton D, et al. A longitudinal study characterising a large adult primary ciliary dyskinesia population. *Eur Respir J*. 2016;48:441–50.
- Gremmo M, Guenza MC. Positive expiratory pressure in the physiotherapeutic management of primary ciliary dyskinesia in paediatric age. *Monaldi Arch Chest Dis*. 1999;54:255–7.
- Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA, Hogg C, et al. Study protocol, rationale and recruitment in a European multi-Centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. *BMC Pulm Med*. 2016;16:104.
- Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. *Eur Respir J*. 2016;48:632–47.
- Behan L, Dimitrov BD, Kuehni CE, Hogg C, Carroll M, Evans HJ, et al. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. *Eur Respir J*. 2016;47:1103–12.
- Amorim A, Gamboa F, Sucena M, Cunha K, Anciães M, Lopes S, et al. Recommendations for aetiological diagnosis of bronchiectasis. *Rev Port Pneumol*. 2016;22(4):222–35.
- Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. *Ann Am Thorac Soc*. 2015;12(12):1764–70.
- Rademacher J, Buck A, Schwerk N, Price M, Fuge J, Welte T, et al. Nasal nitric oxide measurement and a modified PICADAR score for the screening of primary ciliary dyskinesia in adults with bronchiectasis. *Pneumologie*. 2017; 71:543–8.
- Kennedy MP, Noone PG, Leigh MW, Zariwala MA, Minnix SL, Knowles MR, et al. High-resolution CT of patients with primary ciliary dyskinesia. *AJR Am J Roentgenol*. 2007;188(5):1232–8.
- Schlösser TPC, Semple T, Carr SB, Padley S, Loebinger MR, Hogg C, et al. Scoliosis convexity and organ anatomy are related. *Eur Spine J*. 2017;26(6):1595–9.
- Dettmer S, Ringshausen F, Vogel-Claussen J, Fuge J, Faschkami A, Shin H, et al. Computed tomography in adult patients with primary ciliary dyskinesia: typical imaging findings. *PLoS One*. 2018;13(2):e0191457.
- Marthin JK, Nielsen KG. Hand-held tidal breathing nasal nitric oxide measurement – a promising targeted case-finding tool for the diagnosis of primary ciliary dyskinesia. *PLoS One*. 2013;8:e57262.
- Canciani BEG, Mastella G, de Santi MM, Gardi C, Lungarella G. The saccharin method for testing mucociliary function in patients suspected of having primary ciliary dyskinesia. *Pediatr Pulmonol*. 1988;5:210–4.
- Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in primary ciliary dyskinesia. *Eur Respir J*. 2012;40:1024–32.
- Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. *Thorax*. 2002;57:586–9.
- Csoma Z, Bush A, Wilson NM, Donnelly L, Balint B, Barnes PJ, et al. Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. *Chest*. 2003;124:633–8.
- Pifferi M, Bush A, Caramella D, Di Cicco M, Zangani M, Chinellato I, et al. Agenesis of paranasal sinuses and nasal nitric oxide in primary ciliary dyskinesia. *Eur Respir J*. 2011;37:566–71.
- Santamaria F, De Stefano S, Montella S, Barbarano F, Iacotucci P, Ciccarelli R, et al. Nasal nitric oxide assessment in primary ciliary dyskinesia using aspiration, exhalation, and humming. *Med Sci Monit*. 2008;14:CR80–5.
- Lucas JS. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. *Eur Respir J*. 2017;49:1601090.
- Leigh MW, Hazucha MJ, Chawla KK, Baker BR, Shapiro AJ, Brown DE, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. *Ann Am Thorac Soc*. 2013;10:574–81.
- Beydon N, Chambellan A, Alberti C, de Blic J, Clément A, Escudier E, et al. Technical and practical issues for tidal breathing measurements of nasal nitric oxide in children. *Pediatr Pulmonol*. 2015;50:1374–82.
- Jackson CL, Behan L, Collins SA, Goggin PM, Adam EC, Coles JL, et al. Accuracy of diagnostic testing in primary ciliary dyskinesia. *Eur Respir J*. 2016;47:837–48.
- Colantonio D, Brouillette L, Parikh A, Scadding GK. Paradoxical low nasal nitric oxide in nasal polyposis. *Clin Exp Allergy*. 2002;32:698–701.
- Lindberg S, Cervin A, Runer T. Nitric oxide (NO) production in the upper airways is decreased in chronic sinusitis. *Acta Otolaryngol*. 1997;117:113–7.
- Nakano H, Ide H, Imada M, Osanai S, Takahashi T, Kikuchi K. Reduced nasal nitric oxide in diffuse panbronchiolitis. *Am J Respir Crit Care Med*. 2000;162: 2218–20.
- Balfour-Lynn IM, Lavery A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. *Arch Dis Child*. 1996;75:319–22.
- Palm J, Lidman C, Graf P, Alving K, Lundberg J. Nasal nitric oxide is reduced in patients with HIV. *Acta Otolaryngol*. 2000;120:420–3.
- Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. *Am J Respir Crit Care Med*. 1995;152:609–12.
- Shoemark A, Moya E, Hirst RA, Patel MP, Robson EA, Hayward J, et al. High prevalence of CCDC103 p.His154Pro mutation causing primary ciliary dyskinesia disrupts protein oligomerisation and is associated with normal diagnostic investigations. *Thorax*. 2018;73:157–66.
- Knowles MR, Ostrowski LE, Leigh MW, Sears PR, Davis SD, Wolf WE, et al. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. *Am J Respir Crit Care Med*. 2014;189(6):707–17.
- Collins SA, Behan L, Harris A, Gove K, Lucas JS. The dangers of widespread nitric oxide screening for primary ciliary dyskinesia. *Thorax*. 2016;71(6):560–1.

49. Chilvers MA, O'Callaghan C. Analysis of ciliary beat pattern and beat frequency using digital high-speed imaging: comparison with the photomultiplier and photodiode methods. *Thorax*. 2000;55:314–7.
50. Hirst RA, Jackson CL, Coles JL, Williams G, Rutman A, Goggin PM, et al. Culture of primary ciliary dyskinesia epithelial cells at air-liquid interface can alter ciliary phenotype but remains a robust and informative diagnostic aid. *PLoS One*. 2014;9:e89675.
51. Afzelius BA. A human syndrome caused by immotile cilia. *Science*. 1976;193:317–9.
52. Antony D, Becker-Heck A, Zariwala MA, Schmidts M, Onoufriadis A, Forouhan M, et al. Mutations in *CCDC39* and *CCDC40* are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms. *Hum Mutat*. 2013;34:462–72.
53. Onoufriadis A, Shoemark A, Schmidts M, Patel M, Jimenez G, Liu H, et al. Targeted NGS gene panel identifies mutations in *RSPH1* causing primary ciliary dyskinesia and a common mechanism for ciliary central pair agenesis due to radial spoke defects. *Hum Mol Genet*. 2014;23:3362–74.
54. Schwabe GC, Hoffmann K, Loges NT, Birker D, Rossier C, de Santi MM, et al. Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by *DNAH11* mutations. *Hum Mutat*. 2008;29:289–98.
55. Omran H, Loges NT. Immunofluorescence staining of ciliated respiratory epithelial cells. *Methods Cell Biol*. 2009;91:123–33.
56. Frommer A, Hjeij R, Loges NT, Edelbusch C, Jahnke C, Raidt J, et al. Immunofluorescence analysis and diagnosis of primary ciliary dyskinesia with radial spoke defects. *Am J Respir Cell Mol Biol*. 2015;53:563–73.
57. Dougherty GW, Loges NT, Klinkenbusch JA, Olbrich H, Pennekamp P, Menchen T, et al. *DNAH11* localization in the proximal region of respiratory cilia defines distinct outer dynein arm complexes. *Am J Respir Cell Mol Biol*. 2016;55:213–24.
58. Shoemark A, Frost E, Dixon M, Ollosson S, Kilpin K, Patel M, et al. Accuracy of immunofluorescence in the diagnosis of primary ciliary dyskinesia. *Am J Respir Crit Care Med*. 2017;196(1):94–101.
59. Marshall CR, Scherer SW, Zariwala MA, Lau L, Paton TA, Stockley T, et al. Whole-exome sequencing and targeted copy number analysis in primary ciliary dyskinesia. *G3 (Bethesda)*. 2015;5:1775–81.
60. Zariwala MA, Knowles MR, Leigh MW. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LjH B, Stephens K, et al, editors. *Primary ciliary dyskinesia*. Seattle (WA): GeneReviews; 2015. 1963-2018. Last Update: September 3, 2015.
61. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. *Eur Respir J*. 2009;34:843–9.
62. Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Maíz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. *Eur Respir J*. 2014;43(5):1357–67.
63. Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, et al. Analysis of the factors related to mortality in patients with bronchiectasis. *Respir Med*. 2007;101(7):1390–7.
64. Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. *Thorax*. 2002;57:15–9.
65. Maíz L, Vendrell M, Oliveira C, Girón R, Nieto R, Martínez-García MÁ. Prevalence and factors associated with isolation of *aspergillus* and *Candida* from sputum in patients with non-cystic fibrosis bronchiectasis. *Respiration*. 2015;89:396–403.
66. Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. *Respir Res*. 2012;13(1):21.
67. Devaraj A, Wells AU, Meister MG, Loebinger MR, Wilson R, Hansell DM. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. *AJR Am J Roentgenol*. 2011;196:1300–4.
68. Monteiro R, et al. Bronchiectasis: retrospective study and risk factors for hospitalization. *Am J Respir Crit Care Med*. 2012;185:A6094.
69. McShane P, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. *Chest*. 2012;142(1):159–67.
70. Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. *Ann Thorac Med*. 2011;6(3):131–6.
71. Thian X, et al. Analysis of etiology and clinical manifestations of patients with bronchiectasis in Chinese adult from Peking union medical college hospital. *Am J Respir Crit Care Med*. 2014;189:A6253.
72. Hamida K, et al. Etiology and evolution of bronchiectasis in men. *Eur Respir J*. 2013;42:P2205.
73. Borecki S, et al. The evaluation of epidemiological data and etiological reasons of bronchiectasis patients. *Eur Respir J*. 2013;42:P2207.
74. Steinfurt DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central Australia: a young face to an old disease. *Respir Med*. 2008;102(4):574–8.
75. Rafael K, Leal R, et al. The profile of adult patients with bronchiectasis at State University of Rio De Janeiro, Brazil. *Am J Respir Crit Care Med*. 2014;189:A6252.
76. Bhatta N, Dhakal SS, Rizal S, Kralingen KW, Niessen L. Clinical spectrum of patients presenting with bronchiectasis in Nepal: evidence of linkage between tuberculosis, tobacco smoking and toxic exposure to biomass smoke. *Kathmandu Univ Med J*. 2008;6(2):195–203.
77. Amorim A, Bento J, Vaz AP, Gomes I, de Gracia J, Hespagnol V, et al. Bronchiectasis: a retrospective study of clinical and aetiological investigation in a general respiratory department. *Rev Port Pneumol*. 2015;21(1):5–10.
78. Kadowaki T, Yano S, Wakabayashi K, Kobayashi K, Ishikawa S, Kimura M, et al. An analysis of etiology, causal pathogens, imaging patterns, and treatment of Japanese patients with bronchiectasis. *Respir Investig*. 2015;53:37–44.
79. Verra F, Escudier E, Bignon J, Pinchon MC, Bouché M, Bernaudin JF, et al. Inherited factors in diffuse bronchiectasis in the adult: a prospective study. *Eur Respir J*. 1991;4(8):937–44.
80. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. *Am J Respir Crit Care Med*. 2000;162(4 Pt 1):1277–84.
81. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. *Respir Med*. 2006;100(12):2183–9.
82. Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. *Respir Med*. 2013;107(7):1001–7.
83. Qi Q, Wang W, Li T, Zhang Y, Li Y. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: a prospective study. *Respirology*. 2015;20:917–24.
84. Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Aetiology of bronchiectasis in Guangzhou, Southern China. *Respirology*. 2015;20:739–48.
85. Dimakou K, Triantafyllidou C, Toumbis M, Tsikritsaki K, Malagari K, Bakakos P. Non-CF bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients. *Respir Med*. 2016;116:1–7.
86. Oliveira C, Padilla A, Martínez-García MÁ, de la Rosa D, Girón RM, Vendrell M, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish historical bronchiectasis registry. *Arch Bronconeumol*. 2017;53(7):366–74.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

